Chimeric Antigen Receptor T-Cell Therapy in Systemic Lupus Erythematosus and Lupus Nephritis; A Promising Approach to Targeting Autoreactive B Cells

Author(s):

Chanchal Maheshwari*, Shehroz Khan, Lajwanti Bai, Aakash Lakhani, Sadiya Aziz Nathani, Aadesh Kumar, Sarah Aoun and Tehreem Fatima

Systemic Lupus Erythematosus (SLE) poses significant challenges due to its life-threatening nature and the prevalence of lupus nephritis, which causes serious kidney damage. Traditional therapies, such as immunosuppressive medications and blocking antibodies, have had limited success, necessitating the development of novel therapeutic strategies. Chimeric Antigen Receptor T-cell therapy (CAR-T) targets autoreactive B cells and reduces disease activity, and offers promising results for improving disease outcomes, improving survival, and decreasing morbidity and mortality. In this review article, we aim to highlight the potential of CAR-T cell therapy in treating the autoimmune processes that underlie SLE and lupus nephritis.

This review article investigates and assesses the indings, usage in treating diseases and predicting its future consequences. We examine current studies and clinical trials that demonstrate the efficacy of CAR-T cell therapy in refractory instances of SLE, emphasizing its potential as a game-changing treatment option.